Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial

著者: Marcia S. Brose, Maria E. Cabanillas, Ezra E.W. Cohen, Lori J. Wirth, Todd Riehl, Huibin Yue, Steven I. Sherman, Eric J. Sherman - The Lancet 2016 被引用: 384